Sonoma Pharmaceuticals (SNOA) Non-Current Debt (2011 - 2022)

Sonoma Pharmaceuticals' Non-Current Debt history runs 11 years deep, the most recent figure standing at $15000.0 for Q4 2022.

• In Q4 2022, Non-Current Debt changed N/A year-over-year to $15000.0; the TTM figure through Dec 2022 stood at $15000.0 (changed N/A YoY), while the FY2021 annual figure was $1.3 million, changed N/A from the prior year.
• Non-Current Debt was $15000.0 for Q4 2022 at Sonoma Pharmaceuticals, roughly flat from $15000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.3 million in Q2 2020 to a low of $12000.0 in Q1 2019.
• Historically, Non-Current Debt has averaged $449750.0 across 5 years, with a median of $27000.0 in 2018.
• The sharpest annual moves came in 2018 and 2019: Non-Current Debt slipped 28.89% in 2018, then sank 62.5% in 2019.
• A 5-year view of Non-Current Debt shows it stood at $14000.0 in 2018, then slipped by 14.29% to $12000.0 in 2019, then jumped by 10816.67% to $1.3 million in 2020, then changed by 0.0% to $1.3 million in 2021, then slumped by 98.85% to $15000.0 in 2022.
• The last three Non-Current Debt figures came in at $15000.0 (Q4 2022), $15000.0 (Q3 2022), and $15000.0 (Q2 2022), per Business Quant data.